Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 公司自1978年建厂以来，经历了从“国营浙江平湖制药厂”转制成“浙江平湖制药厂(股份合作)”到“浙江平湖莎普爱思制药有限公司”，再到“浙江莎普爱思制药有限公司”，最终于2008年12月15日更名为“浙江莎普爱思药业股份有限公司”，目前注册资金为4900万元人民币。公司作为一家专业从事药品研发、生产、经营的综合性制药企业，先后被列为“国家高新技术企业”、“浙江省百家最具投资价值企业”、“浙江省千家成长之星企业”、“浙江省级企业技术中心”、“省级高新技术研究开发中心”、“浙江省标准创新型企业”、“嘉兴市重点企业技术创新团队”、“院士专家工作站”等多项荣誉称号。目前公司拥有大容量注射剂（玻璃瓶、塑料瓶和多层共挤膜袋）、口服溶液剂、滴眼剂、片剂（含头孢菌素类）、硬胶囊剂（含头孢菌素类）、栓剂、颗粒剂（含头孢菌素类）、干混悬剂（含头孢菌素类）、冲洗剂共10个剂型，近百种规格的产品批准文号。抗白内障新药“莎普爱思”滴眼液和抗青光眼新药“达靓”滴眼液被列入“国家火炬计划项目”。“莎普爱思”滴眼液还荣获国家重点科技攻关项目、国家重点新产品、浙江省名牌产品等多个称号，是国内第一个国家二类眼科专科新药。
Main Business 医药制造板块、医疗服务板块
Legal Representative 林弘立
Top Executives
董事长：林弘立
董事：林弘立,林凯,黄明雄,林秀松,汪为民,吴建国
独立董事：孙继伟,陈胜群,颜世富
Top 5 Shareholder
Shareholder name Nature Holding Date
上海养和实业有限公司限售股+流通A股20.64%30/09/2024
陈德康流通A股12.39%30/09/2024
林弘远限售股+流通A股7.64%30/09/2024
上海景兴实业投资有限公司流通A股4.70%30/09/2024
上海同辉医疗管理有限公司流通A股2.31%30/09/2024
Company Secretary 黄明雄
Solicitors 北京市金杜律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 0573-85021168
Fax No 0573-85076188
Website www.zjspas.com
Email spasdm@zjspas.com;zjspas@zjspas.com
Company Address
Register: 浙江省平湖市经济开发区新明路1588号
Office: 浙江省平湖市经济开发区新明路1588号
Listing Date 02/07/2014
Shares Capital
Shares Capital: 375,925,005
Total A Share: 375,925,005
Listed A Share: 322,592,499
Non-tradable A Share: 53,332,506
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.070
DPS(RMB)* ¥ 0.021
NBV Per Share(RMB)* ¥ 4.535
Market Capitalization(RMB) 2.410B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.